Compare Amgen, Inc. (AMGN) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs L3Harris Technologies Inc — how do they compare? Amgen, Inc. trades at $358.76 (market cap $196.12B), while L3Harris Technologies Inc trades at $289.15 (market cap $54.17B). The key difference: Amgen, Inc. is far larger — about 3.6× L3Harris Technologies Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LHX | |
|---|---|---|
Market Cap | $196.12B | $54.17B |
Sector | Health | Industrials |
52-Week High | $388.16 | $378.48 |
52-Week Low | $271.18 | $259.55 |
Enterprise Value | $241.41B | $64.94B |
Dividend Yield | 2.77% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LHX trades at $290.77, up 0.31% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains a 7.71% net income margin. Recent news includes a $84 million U.S. Army contract for NGC2 manpack systems (Business Wire, July 9, 2026). Cash flow from operations improved to $3.11B in 2025, while debt-to-asset ratio declined to 26.98%.
Outlook is positive with a consensus price target of $367.50, implying 26% upside, supported by 75% analyst buy ratings. Risks include execution delays in defense contracts and macroeconomic pressures. The stock offers value through earnings growth and dividend yield, but investors should monitor debt levels and competitive threats from new entrants like SpaceX.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
